NASDAQ · BNR
Healthcare · Medical - Diagnostics & Research
$8.83
Down-$0.46 (-4.95%)
Updated Aug 16, 2026, 4:49 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 19 trading sessions · Daily adjusted prices
BNR closed at $8.83 after 19 trading sessions, down 12.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $9.34 | $9.81 | $8.83 | $8.83 | 16.1K |
| Aug 13, 2026 | $9.83 | $9.83 | $9.29 | $9.29 | 2.97K |
| Aug 12, 2026 | $10.20 | $10.20 | $9.93 | $9.93 | 1.11K |
| Aug 11, 2026 | $10.66 | $11.1256 | $10.00 | $10.4213 | 13.49K |
| Aug 10, 2026 | $9.55 | $11.27 | $9.55 | $10.8569 | 21.57K |
| Aug 7, 2026 | $8.89 | $8.91 | $8.81 | $8.81 | 1.81K |
| Aug 6, 2026 | $8.88 | $9.24 | $8.86 | $8.88 | 1.68K |
| Aug 5, 2026 | $8.97 | $8.97 | $8.88 | $8.88 | 1.51K |
| Aug 4, 2026 | $8.88 | $9.105 | $8.88 | $8.97 | 2.91K |
| Aug 3, 2026 | $8.96 | $9.08 | $8.80 | $8.84 | 14.32K |
| Jul 31, 2026 | $9.06 | $9.06 | $8.875 | $8.90 | 1.47K |
| Jul 30, 2026 | $8.70 | $9.12 | $8.70 | $8.85 | 2.48K |
| Jul 29, 2026 | $8.91 | $9.19 | $8.80 | $8.82 | 1.43K |
| Jul 28, 2026 | $9.085 | $9.29 | $9.085 | $9.19 | 1.87K |
| Jul 27, 2026 | $9.335 | $9.40 | $9.335 | $9.40 | 457 |
| Jul 23, 2026 | $9.12 | $9.12 | $8.95 | $8.95 | 6.78K |
| Jul 22, 2026 | $9.29 | $9.50 | $9.11 | $9.14 | 18.69K |
| Jul 21, 2026 | $9.36 | $9.75 | $9.35 | $9.45 | 6.82K |
| Jul 20, 2026 | $10.07 | $10.07 | $9.60 | $10.07 | 10.75K |
The latest Smart Investors Daily articles mentioning BNR.
BNR research
Company profile and research snapshot.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2021 | CICC | Outperform | — |
| Jul 13, 2020 | B of A Securities | Buy | — |
| Jul 7, 2020 | Cowen & Co. | Outperform | — |
No generated briefing is available yet.
Benzinga · Jul 2, 2026
As of the date of this press release, combined with 72,733 ADSs purchased in the last two post-earnings trading windows, Mr. Han has purchased an aggregate of 145,874 of the Company’s ADSs for US$1,976,542.90 across
Benzinga · Jun 12, 2026
Benzinga · Jun 9, 2026
Burning Rock Biotech (NASDAQ:BNR) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $15.649 million in sales this quarter. This is a 14.67 percent
globenewswire.com · Dec 1, 2025
GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 23, 2025 at 10:30 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BNR.
No results
No recent SID articles mention BNR.
